IN2015DN03826A - - Google Patents

Info

Publication number
IN2015DN03826A
IN2015DN03826A IN3826DEN2015A IN2015DN03826A IN 2015DN03826 A IN2015DN03826 A IN 2015DN03826A IN 3826DEN2015 A IN3826DEN2015 A IN 3826DEN2015A IN 2015DN03826 A IN2015DN03826 A IN 2015DN03826A
Authority
IN
India
Prior art keywords
subject
pharmaceutical composition
concentration
dose
time point
Prior art date
Application number
Other languages
English (en)
Inventor
Elizabeth Holmes
Original Assignee
Theranos Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theranos Inc filed Critical Theranos Inc
Publication of IN2015DN03826A publication Critical patent/IN2015DN03826A/en

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Primary Health Care (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IN3826DEN2015 2012-10-23 2013-10-22 IN2015DN03826A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261717609P 2012-10-23 2012-10-23
PCT/US2013/066238 WO2014066428A1 (en) 2012-10-23 2013-10-22 Drug monitoring and regulation systems and methods

Publications (1)

Publication Number Publication Date
IN2015DN03826A true IN2015DN03826A (pt) 2015-10-02

Family

ID=50486139

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3826DEN2015 IN2015DN03826A (pt) 2012-10-23 2013-10-22

Country Status (9)

Country Link
US (2) US20140114676A1 (pt)
EP (1) EP2911642B1 (pt)
KR (1) KR20150079660A (pt)
CN (1) CN104884029A (pt)
AU (2) AU2013334700A1 (pt)
CA (1) CA2887669A1 (pt)
HK (1) HK1214498A1 (pt)
IN (1) IN2015DN03826A (pt)
WO (1) WO2014066428A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102370479B1 (ko) 2012-10-05 2022-03-04 다이앤 몰드 수학적 모형 함수로서의 환자-특이적 투여법용 의약
US11183287B2 (en) * 2013-06-13 2021-11-23 Carefusion 303, Inc. Analytics regarding patient care
US10777313B2 (en) 2013-06-13 2020-09-15 Carefusion 303, Inc. Analytics regarding ventilated patients
US20210005324A1 (en) * 2018-08-08 2021-01-07 Hc1.Com Inc. Methods and systems for a health monitoring command center and workforce advisor
US20180045744A1 (en) * 2015-01-16 2018-02-15 Ameritox, Llc Normalizing measured drug concentrations in oral fluids and testing for potential non-compliance with drug treatment regimen
SG10202009369SA (en) * 2015-04-09 2020-10-29 Diane Mould Systems and methods for patient-specific dosing
CA3020346A1 (en) 2016-04-15 2017-10-19 Baxalta Incorporated Method and apparatus for providing a pharmacokinetic drug dosing regimen
US10896749B2 (en) * 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool
CN109718112B (zh) * 2017-10-30 2020-12-29 京东方科技集团股份有限公司 用药提醒方法、装置及计算机可读存储介质
WO2019183218A1 (en) * 2018-03-20 2019-09-26 Cytomx Therapeutics, Inc. Systems and methods for quantitative pharmacological modeling of activatable antibody species in mammalian subjects
MX2020013181A (es) * 2018-06-06 2021-02-26 Minoryx Therapeutics S L Metodo para administrar una cantidad terapeuticamente efectiva de 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-th iazolidin-2,4-diona.
US20220128474A1 (en) * 2018-10-23 2022-04-28 Amgen Inc. Automatic calibration and automatic maintenance of raman spectroscopic models for real-time predictions
CA3124675A1 (en) * 2018-12-21 2020-06-25 Thsee, Llc Method for optimization of cannabis dosage and mixture of active cannabinoids
WO2021097653A1 (en) * 2019-11-19 2021-05-27 National University Of Singapore Optimisation of combination drug therapies
US20210304846A1 (en) * 2020-03-29 2021-09-30 Stephen J. Brown Personalized compounding of therapeutic components and tracking of their influence on a measured parameter using a complex interaction model
CN111489822A (zh) * 2020-04-02 2020-08-04 首都医科大学附属北京安定医院 一种治疗药物监测结果解释系统
KR102481888B1 (ko) 2020-09-01 2022-12-28 고려대학교 산학협력단 딥러닝을 이용한 수면유도제 투여량 예측방법 및 예측 장치
CN113823365A (zh) * 2021-09-30 2021-12-21 北京兴德通医药科技股份有限公司 临床研究质量控制方法、系统、电子设备和存储介质

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0010316A (pt) * 1999-05-11 2004-04-27 Ortho Mcnell Pharmaceutical In Método e sistema para obtenção de regimes de dosagem otimizados de epo para uma resposta farmacodinâmica/farmacocinética desejada em um paciente
US7124031B1 (en) * 2000-05-11 2006-10-17 Medco Health Solutions, Inc. System for monitoring regulation of pharmaceuticals from data structure of medical and labortory records
US6599281B1 (en) * 2000-05-03 2003-07-29 Aspect Medical Systems, Inc. System and method for adaptive drug delivery
US7860583B2 (en) * 2004-08-25 2010-12-28 Carefusion 303, Inc. System and method for dynamically adjusting patient therapy
US20040014097A1 (en) * 2002-05-06 2004-01-22 Mcglennen Ronald C. Genetic test apparatus and method
US7585680B2 (en) * 2003-08-28 2009-09-08 Marshfield Medical Research And Education Foundation Method and device for monitoring medication usage
GB0420256D0 (en) * 2004-09-13 2004-10-13 Cassells John M Method and apparatus for sampling and analysis of fluids
KR101762424B1 (ko) 2005-05-09 2017-07-28 테라노스, 인코포레이티드 현장진료 유체 시스템 및 그 용도
US20060283465A1 (en) * 2005-06-16 2006-12-21 Nickel Janice H Smart drug delivery system and a method of implementation thereof
CA2911569C (en) * 2005-11-29 2019-11-26 Children's Hospital Medical Center Optimization and individualization of medication selection and dosing
KR100867324B1 (ko) * 2007-03-13 2008-11-06 가톨릭대학교 산학협력단 혈중약물농도측정 처방 자동화 방법
US20080262867A1 (en) * 2007-04-18 2008-10-23 Janus Health, Inc. Patient management system and method
CN100580448C (zh) * 2007-08-10 2010-01-13 复旦大学附属华山医院 一种测定人血浆中苯妥英及其前体药物和代谢物的方法
EP2657699B1 (en) 2007-10-02 2017-03-22 Theranos, Inc. Modular point-of-care devices and uses thereof
EP2286359A2 (en) * 2008-03-27 2011-02-23 Medtronic, Inc. Method and system to define patient specific therapeutic regimens by means of pharmacokinetic and pharmacodynamic tools
AU2010217221A1 (en) * 2009-02-26 2011-08-25 Dreamed Diabetes Ltd. Method and system for automatic monitoring of diabetes related treatments
US20120108947A1 (en) * 2009-07-22 2012-05-03 Eli Lilly And Company Method for predicting weight gain associated with a pharmaceutical therapy
US20120203573A1 (en) * 2010-09-22 2012-08-09 I.D. Therapeutics Llc Methods, systems, and apparatus for optimizing effects of treatment with medication using medication compliance patterns

Also Published As

Publication number Publication date
AU2013334700A1 (en) 2015-04-30
EP2911642A1 (en) 2015-09-02
EP2911642B1 (en) 2022-11-16
EP2911642A4 (en) 2016-06-08
US20140114676A1 (en) 2014-04-24
AU2018204120A1 (en) 2018-06-28
CA2887669A1 (en) 2014-05-01
US20160342768A1 (en) 2016-11-24
KR20150079660A (ko) 2015-07-08
HK1214498A1 (zh) 2016-07-29
WO2014066428A1 (en) 2014-05-01
CN104884029A (zh) 2015-09-02

Similar Documents

Publication Publication Date Title
IN2015DN03826A (pt)
AU2017272293B2 (en) Providing a pharmacokinetic drug dosing regimen
NZ722834A (en) Systems and methods for compensating long term sensitivity drift of electrochemical gas sensors exposed to nitric oxide
SG10201902353UA (en) Capturing specific nucleic acid materials from individual biological cells in a micro-fluidic device
BR112012020270A2 (pt) sistema e método para administrar medicamentos com base em valores de urina.
MX2019006900A (es) Metodos de monitoreo terapeutico de farmacos depuradores de nitrogeno.
IN2014KN02583A (pt)
MX2016008138A (es) Sistema para el suministro transdermico de ingredientes activos.
MX2020001369A (es) Sistema de analisis para el cuidado de un paciente.
BR112014010139A2 (pt) formulação farmacêutica, método de redução do nível de açúcar no sangue de um paciente e polipeptídeo
EA201400737A1 (ru) Система доставки на основе множества пеллет с немедленным высвобождением активного вещества
EA201590797A1 (ru) Препараты с модифицированным высвобождением опрозомиба
BR112013029199A2 (pt) sistema de distribuição de fármacos, dispositivo de distribuição de dois fármacos, método para preparar o mesmo, comprimido para administração sublingual de um ingrediente ativo, e, método para a administração de um ingrediente ativo a um indivíduo
NZ754328A (en) Marker for acid sphingomyelinase disorders and uses thereof
MX2015009891A (es) Composiciones farmaceuticas que comprenden particulas cristalinas de multicomponentes adecuadas para usar en terapia de inhalacion.
ATE499040T1 (de) Vorrichtung zur arzneimittelverabreichung und/oder überwachung des zustandes eines patienten
EA201391023A1 (ru) Способ снижения боли у животных семейства собачьих с помощью трансдермального раствора фентанила
BR112017022984A2 (pt) dispositivo para facilitar o posicionamento de um cateter para administrar um medicamento em um paciente que esteja respirando espontaneamente
SG10201809418VA (en) New administration routes of insulin, insulin analogs or derivatives of insulin
MX2011011879A (es) Uso de las betaxantinas y sus derivados para preparar un medicamento para el tratamiento de la prediabetes y diabetes.
Johnson et al. Quantitative T1rho mapping of bipolar disorder: basal differences in euthymia
田村典朗 Post-approval appending of CSARs to drug package inserts: an analysis of the types of adverse reactions and time to addition
UA72898U (ru) Способ стимуляции воспроизводительной способности хряков-производителей при их экстенсивном половом использовании
Nunnelee Review of an Article: Self-management for oral anticoagulation (2009). Garcia-Alamino JM, Martin JLR, Subirana M & Gich I. Cochrane, Database of Systematic Reviews 4 (CD003839
UA53381U (ru) Способ получения средства с мембраностабилизирующим действием